comparemela.com

Latest Breaking News On - External partnering center - Page 5 : comparemela.com

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

United statesXueming qianWei qiang gaoLos angelesJohnt isaacsShanghai jiao tong university research instituteClinical development centersTranscenta holdingJiao tong universityShanghai jiaotong university school of medicineProduct development centerTranslational research centerGroup headquartersShanghai jiao tong universityTranscenta holding limitedClinical stem cell research center

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

Mccormick placeUnited statesLos angelesJifang gongTianshu liuClinical development centersTranscenta holdingAmerican society of clinical oncologyUniversity cancer hospitalProduct development centerTranslational research centerGroup headquartersPrnewswire transcenta holding limitedFudan universityResearch instituteTranscenta immune tolerance breaking technology

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

Mccormick placeUnited statesLos angelesJifang gongTianshu liuClinical development centersTranscenta holdingAmerican society of clinical oncologyUniversity cancer hospitalProduct development centerTranslational research centerGroup headquartersPrnewswire transcenta holding limitedFudan universityResearch instituteTranscenta immune tolerance breaking technology

Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

United statesLos angelesMichael shiEli lillyClinical development centersTranscenta holdingCompany eli lillyProduct development centerTranslational research centerGroup headquartersPrnewswire transcenta holding limitedBusiness developmentHolding limitedChina phasei studyGreater chinaManufacturing facility

Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

United statesLos angelesMichael shiEli lillyClinical development centersTranscenta holdingCompany eli lillyProduct development centerTranslational research centerGroup headquartersPrnewswire transcenta holding limitedBusiness developmentHolding limitedChina phasei studyGreater chinaManufacturing facility

vimarsana © 2020. All Rights Reserved.